Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients

International Journal of Antimicrobial Agents

Volumn 44, Issue 2, 2014, Pages 145-151

  Liu, Xi ^a   Wang, Yawen ^a   Zhang, Guanjun ^a   Li, Na ^a   Zhu, Qianqian ^a   Chang, Hongyun ^a   Han, Qunying ^a   Lv, Yi ^a   Liu, Zhengwen ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Hepatitis C; Meta analysis; Pegylated interferon ; Ribavirin; Sofosbuvir

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; URIDINE PHOSPHATE;

ANEMIA; ANXIETY; ARTHRALGIA; ARTICLE; BEHAVIOR DISORDER; CHILL; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEVER; HEADACHE; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; INSOMNIA; IRRITABILITY; LEUKOPENIA; LYMPHOCYTOPENIA; META ANALYSIS; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; RASH; RELAPSE; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ADULT; AGED; ANALOGS AND DERIVATIVES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATITIS C, CHRONIC; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATITIS C, CHRONIC; HUMANS; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; VIRAL LOAD; YOUNG ADULT;

EID: 84905585545     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.04.018     Document Type: Article

References (24)

1. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seeff An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
2. E. Lawitz, J.P. Lalezari, T. Hassanein, K.V. Kowdley, F.F. Poordad, and A.M. Sheikh et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial Lancet Infect Dis 13 2013 401 408
3. European Association for Study of Liver EASL clinical practice guidelines: management of hepatitis C virus infection J Hepatol 60 2014 392 420
4. V. Soriano, E. Vispo, E. Poveda, P. Labarga, and P. Barreiro Treatment failure with new hepatitis C drugs Expert Opin Pharmacother 13 2012 313 323
5. J.J. Kiser, J.R. Burton, P.L. Anderson, and G.T. Everson Review and management of drug interactions with boceprevir and telaprevir Hepatology 55 2012 1620 1628
6. B.L. Pearlman Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care Lancet Infect Dis 12 2012 717 728
7. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
8. M.S. Sulkowski, C. Cooper, B. Hunyady, J. Jia, P. Ogurtsov, and M. Peck-Radosavljevic et al. Management of adverse effects of peg-IFN and ribavirin therapy for hepatitis C Nat Rev Gastroenterol Hepatol 8 2011 212 223
9. Y. Falck-Ytter, H. Kale, K.D. Mullen, S.A. Sarbah, L. Sorescu, and A.J. McCullough Surprisingly small effect of antiviral treatment in patients with hepatitis C Ann Intern Med 136 2002 288 292
10. E.J. Gane, C.A. Stedman, R.H. Hyland, X. Ding, E. Svarovskaia, and W.T. Symonds et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N Engl J Med 368 2013 34 44
11. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, and S.C. Gordon et al. Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
12. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, E.M. Yoshida, M. Rodriguez-Torres, and M.S. Sulkowski et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
13. K.V. Kowdley, E. Lawitz, I. Crespo, T. Hassanein, M.N. Davis, and M. DeMicco et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial Lancet 381 2013 2100 2107
14. M. Rodriguez-Torres, E. Lawitz, K.V. Kowdley, D.R. Nelson, E. Dejesus, and J.G. McHutchison et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial J Hepatol 58 2013 663 668
15. A. Osinusi, E.G. Meissner, Y.J. Lee, D. Bon, L. Heytens, and A. Nelson et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial JAMA 310 2013 804 811
16. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred Reporting Items for Systematic reviews and Meta-Analyses: the PRISMA statement Ann Intern Med 151 2009 264 269
17. J. Chen, J. Florian, W. Carter, R.D. Fleischer, T.S. Hammerstrom, and P.R. Jadhav et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies Gastroenterology 144 2013 1450 1455.e2
18. T. Asselah Sofosbuvir-based interferon-free therapy for patients with HCV infection J Hepatol 59 2013 1342 1345
19. X. Tong, S. Le Pogam, L. Li, K. Haines, K. Piso, and V. Baronas et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir J Infect Dis 209 2014 668 675
20. E.J. Lawitz, M. Rodriguez-Torres, J. Denning, A. Mathias, H. Mo, and B. Gao et al. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear) J Viral Hepat 20 2013 699 707
21. E. Lawitz, F.F. Poordad, P.S. Pang, R.H. Hyland, X. Ding, and H. Mo et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial Lancet 383 2014 515 523
22. E.J. Gane, C.A. Stedman, R.H. Hyland, X. Ding, E. Svarovskaia, and G.M. Subramanian et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection Gastroenterology 146 2014 736-43.e1
23. Z.M. Younossi, M. Stepanova, L. Henry, E. Gane, I.M. Jacobson, and E. Lawitz et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C Clin Gastroenterol Hepatol 2013 10.1016/j.cgh.2013.11.032 [Epub ahead of print]
24. Z.M. Younossi, M. Stepanova, L. Henry, E. Gane, I.M. Jacobson, and E. Lawitz et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C) J Hepatol 60 2014 741 747